FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2598646167> ?p ?o ?g. }

• W2598646167 abstract "e16020 Background: No standard exists for the treatment of bcrPC. Concern over deleterious effects of androgen deprivation (ADT) and lack of proven survival benefit in this setting makes initiation of ADT inappropriate for some patients. A non-hormonal, non-toxic agent to reduce PSA would be a welcome alternative to observation. We tested Prostate Health Cocktail (PHC), a supplement containing vitamin D & E, saw palmetto, lycopene, green tea and soy extracts, in this population, to see whether it could decrease PSA. Methods: Eligible men had a rising PSA with doubling time between 3 and 36 months, with no evidence of metastases on CT and bone scan. After IRB approval, 40 men were treated with PHC 3 capsules PO daily for 4 week cycles. PSA was repeated after cycle 1, then every 2 cycles thereafter with imaging only as clinically indicated; the primary endpoint was PSA decline. PSA progression was defined as 25% increase above baseline/nadir AND absolute increase of 5 ng/mL or return to baseline. Circulating tumor cells (CTCs) were measured at baseline and after 3 cycles using parylene membrane filters. Results: 60 men screened, 17 failed (28%). Median age was 67 (range 54-84) and baseline PSA 2.8 ng/mL (1.1-84.1). 23% had primary radiation only, 25% had prostatectomy, and 52% had both; 23% had Gleason 8-10. The median # of cycles was 8 (1-13). 15/40 men (37.5%) had a PSA decline (1.1%-55% maximum decrease). 43% stopped therapy for PSA progression, with median time to progression 10.2 months. Circulating tumor cells were detected in 5 of the first 23 subjects; complete CTC data will be presented. There was no significant change in testosterone or DHT during treatment. Toxicities possibly related to PHC included grade 1 or 2 liver enzyme elevations [transient], grade 1 or 2 gastrointestinal symptoms (9), grade 1 weakness/dizziness/pain (5), and grade 1 fatigue (2). 5 men continue on study, 3 lost to f/u, 16 have developed metastases, median time to mets 31.5 months from bcr. Conclusions: PHC induced PSA declines in 37% of patients with bcrPC, and was not associated with changes in serum androgens or significant toxicities. PHC is a potential alternative to observation in select patients with bcrPC. Clinical trial information: NCT00669656." @default.
• W2598646167 created "2017-04-07" @default.
• W2598646167 creator A5011277587 @default.
• W2598646167 creator A5020334875 @default.
• W2598646167 creator A5031088617 @default.
• W2598646167 creator A5047212274 @default.
• W2598646167 creator A5059219836 @default.
• W2598646167 creator A5062167990 @default.
• W2598646167 creator A5067387322 @default.
• W2598646167 creator A5079064470 @default.
• W2598646167 creator A5084766370 @default.
• W2598646167 creator A5091696839 @default.
• W2598646167 date "2013-05-20" @default.
• W2598646167 modified "2023-09-28" @default.
• W2598646167 title "Final results from a trial of a combination herbal supplement for biochemically recurrent prostate cancer." @default.
• W2598646167 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e16020" @default.
• W2598646167 hasPublicationYear "2013" @default.
• W2598646167 type Work @default.
• W2598646167 sameAs 2598646167 @default.
• W2598646167 citedByCount "0" @default.
• W2598646167 crossrefType "journal-article" @default.
• W2598646167 hasAuthorship W2598646167A5011277587 @default.
• W2598646167 hasAuthorship W2598646167A5020334875 @default.
• W2598646167 hasAuthorship W2598646167A5031088617 @default.
• W2598646167 hasAuthorship W2598646167A5047212274 @default.
• W2598646167 hasAuthorship W2598646167A5059219836 @default.
• W2598646167 hasAuthorship W2598646167A5062167990 @default.
• W2598646167 hasAuthorship W2598646167A5067387322 @default.
• W2598646167 hasAuthorship W2598646167A5079064470 @default.
• W2598646167 hasAuthorship W2598646167A5084766370 @default.
• W2598646167 hasAuthorship W2598646167A5091696839 @default.
• W2598646167 hasConcept C121608353 @default.
• W2598646167 hasConcept C126322002 @default.
• W2598646167 hasConcept C143998085 @default.
• W2598646167 hasConcept C2776235491 @default.
• W2598646167 hasConcept C2780192828 @default.
• W2598646167 hasConcept C29456083 @default.
• W2598646167 hasConcept C556039675 @default.
• W2598646167 hasConcept C71924100 @default.
• W2598646167 hasConceptScore W2598646167C121608353 @default.
• W2598646167 hasConceptScore W2598646167C126322002 @default.
• W2598646167 hasConceptScore W2598646167C143998085 @default.
• W2598646167 hasConceptScore W2598646167C2776235491 @default.
• W2598646167 hasConceptScore W2598646167C2780192828 @default.
• W2598646167 hasConceptScore W2598646167C29456083 @default.
• W2598646167 hasConceptScore W2598646167C556039675 @default.
• W2598646167 hasConceptScore W2598646167C71924100 @default.
• W2598646167 hasLocation W25986461671 @default.
• W2598646167 hasOpenAccess W2598646167 @default.
• W2598646167 hasPrimaryLocation W25986461671 @default.
• W2598646167 hasRelatedWork W1720917541 @default.
• W2598646167 hasRelatedWork W1732151415 @default.
• W2598646167 hasRelatedWork W1815176607 @default.
• W2598646167 hasRelatedWork W1910164612 @default.
• W2598646167 hasRelatedWork W2003340521 @default.
• W2598646167 hasRelatedWork W2004663358 @default.
• W2598646167 hasRelatedWork W2053860654 @default.
• W2598646167 hasRelatedWork W2055722076 @default.
• W2598646167 hasRelatedWork W2074491854 @default.
• W2598646167 hasRelatedWork W2092691914 @default.
• W2598646167 hasRelatedWork W2097702726 @default.
• W2598646167 hasRelatedWork W2103531329 @default.
• W2598646167 hasRelatedWork W2159230921 @default.
• W2598646167 hasRelatedWork W2255853361 @default.
• W2598646167 hasRelatedWork W2339676148 @default.
• W2598646167 hasRelatedWork W2559686304 @default.
• W2598646167 hasRelatedWork W2611234403 @default.
• W2598646167 hasRelatedWork W2913942481 @default.
• W2598646167 hasRelatedWork W2918922449 @default.
• W2598646167 hasRelatedWork W44266094 @default.
• W2598646167 isParatext "false" @default.
• W2598646167 isRetracted "false" @default.
• W2598646167 magId "2598646167" @default.
• W2598646167 workType "article" @default.